Med
CAR-T for autoimmune disease achieves first complex remission
Clinical takeaway: Cellular therapeutics and immune insights first developed in oncology are being applied to autoimmune disease. The research remains early stage.
CAR-T therapy is well known in cancer treatment, but it’s now being tested in autoimmune disease. In this case report, a single patient with three severe, treatment-resistant autoimmune conditions achieved rapid, treatment-free remission after one infusion.
The patient had treatment-resistant autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome despite nine prior therapies, then received CD19 CAR-T therapy.
The response was rapid. Transfusion independence occurred within 1 week, and hemoglobin normalized by about 3 to 4 weeks. Markers of all three diseases improved: hemolysis resolved, platelet counts stabilized, and antiphospholipid antibodies became negative. The patient has remained in remission without further treatment for about a year.
The treatment used the patient’s own T cells, engineered to target CD19 on B cells, to broadly eliminate antibody-producing immune cells driving disease. CAR-T cells depleted her B cells, and when they returned months later, they were predominantly naïve rather than autoreactive, suggesting a reset of the immune system.
No cytokine release syndrome or neurotoxicity was observed, though persistent lab abnormalities were noted, including low blood counts and mild liver enzyme elevations, likely related to prior treatments or disease burden.
“We believe that using CAR-T therapy earlier for patients with severe autoimmune disease could help prevent complications from years of ineffective treatments,” said corresponding author Fabian Müller. “If we can intervene sooner, we may be able to stop the disease process, avoid organ damage, and give patients their lives back.”
FDA-approved CAR-T therapies are used in certain blood cancers, including leukemias, lymphomas, and multiple myeloma, typically after other treatments have failed. They are complex, one-time treatments that require specialized centers and close monitoring. Costs are high, often $400,000–$500,000 or more for the therapy alone excluding hospitalization and management of side effects.
Source: Korte IK. Med. April 9, 2026. CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome